[{"address1": "Modi\u2019in Technology Park", "address2": "2 HaMa\u2019ayan Street", "city": "Hevel Modi'in", "zip": "7177871", "country": "Israel", "phone": "972 8 642 9100", "fax": "972 8 642 9101", "website": "https://www.biolinerx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; and MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer, as well as licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Modi'in, Israel.", "fullTimeEmployees": 49, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip A. Serlin CPA, M.B.A., CPA, MBA", "age": 62, "title": "Chief Executive Officer", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 635000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Mali  Zeevi CPA, CPA", "age": 46, "title": "Chief Financial Officer", "yearBorn": 1976, "fiscalYear": 2022, "totalPay": 380000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ella  Sorani", "age": 54, "title": "Chief Development Officer", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": 457000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Holly W. May M.B.A.", "age": 60, "title": "President of BioLineRx USA", "yearBorn": 1962, "fiscalYear": 2022, "totalPay": 328000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Lacey", "title": "Head of Corporate Communications & Investor Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Janoff Esq.", "title": "General Counsel & Head of Compliance", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Tsipi  Keren-Lehrer B.Sc., L.L.B.", "title": "Head of BD & Strategic Advisor", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Raziel  Fried", "title": "Treasurer & Budgetary Control Director", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 1.69, "open": 1.71, "dayLow": 1.7, "dayHigh": 1.89, "regularMarketPreviousClose": 1.69, "regularMarketOpen": 1.71, "regularMarketDayLow": 1.7, "regularMarketDayHigh": 1.89, "payoutRatio": 0.0, "beta": 1.103, "forwardPE": -178.0, "volume": 667202, "regularMarketVolume": 667202, "averageVolume": 854129, "averageVolume10days": 296780, "averageDailyVolume10Day": 296780, "bid": 1.75, "ask": 1.9, "bidSize": 800, "askSize": 1300, "marketCap": 128570112, "fiftyTwoWeekLow": 0.55, "fiftyTwoWeekHigh": 2.53, "fiftyDayAverage": 1.5286, "twoHundredDayAverage": 1.41875, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "enterpriseValue": 1713799040, "profitMargins": 0.0, "floatShares": 873867027, "sharesOutstanding": 72230400, "sharesShort": 357261, "sharesShortPriorMonth": 1025273, "sharesShortPreviousMonthDate": 1697155200, "dateShortInterest": 1700006400, "sharesPercentSharesOut": 0.0049, "heldPercentInsiders": 0.09455, "heldPercentInstitutions": 0.019340001, "shortRatio": 0.97, "impliedSharesOutstanding": 61530600, "bookValue": 0.014, "priceToBook": 127.14285, "lastFiscalYearEnd": 1672444800, "nextFiscalYearEnd": 1703980800, "mostRecentQuarter": 1696032000, "netIncomeToCommon": -52461000, "trailingEps": -0.75, "forwardEps": -0.01, "pegRatio": 0.07, "lastSplitFactor": "1:15", "lastSplitDate": 1563148800, "enterpriseToEbitda": -44.023, "52WeekChange": 1.5797102, "SandP52WeekChange": 0.15381551, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "BLRX", "underlyingSymbol": "BLRX", "shortName": "BioLineRx Ltd.", "longName": "BioLineRx Ltd.", "firstTradeDateEpochUtc": 1311773400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "e62a36f1-05bb-3c53-9aee-d33adfbdf394", "messageBoardId": "finmb_5015080", "gmtOffSetMilliseconds": -18000000, "currentPrice": 1.78, "targetHighPrice": 21.0, "targetLowPrice": 7.6, "targetMeanPrice": 14.3, "targetMedianPrice": 14.3, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 2, "totalCash": 25968000, "totalCashPerShare": 0.027, "ebitda": -38930000, "totalDebt": 13313000, "quickRatio": 1.785, "currentRatio": 1.956, "debtToEquity": 101.363, "returnOnAssets": -0.36727002, "returnOnEquity": -1.5281799, "freeCashflow": -22640124, "operatingCashflow": -33282000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "trailingPegRatio": null}]